NASDAQ:BLPH - Bellerophon Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bellerophon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.37 0.00 (0.00 %) (As of 01/28/2020 06:30 AM ET) Add Compare Today's Range$0.36Now: $0.37▼$0.3950-Day Range$0.33MA: $0.37▼$0.4352-Week Range$0.31Now: $0.37▼$0.79Volume95,559 shsAverage Volume507,759 shsMarket Capitalization$25.69 millionP/E RatioN/ADividend YieldN/ABeta-0.11 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLPH Previous Symbol CUSIPN/A CIK1600132 Webhttp://www.bellerophon.com/ Phone908-574-4770Debt Debt-to-Equity Ratio0.25 Current Ratio1.96 Quick Ratio1.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.05 per share Price / Cash Flow8.03 Book Value$0.06 per share Price / Book6.23Profitability EPS (Most Recent Fiscal Year)($0.34) Net Income$2.81 million Net MarginsN/A Return on Equity-102.96% Return on Assets-42.26%Miscellaneous Employees17 Outstanding Shares68,700,000Market Cap$25.69 million Next Earnings Date3/12/2020 (Estimated) OptionableNot Optionable Receive BLPH News and Ratings via Email Sign-up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BLPH Rates by TradingView Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions What is Bellerophon Therapeutics' stock symbol? Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH." How were Bellerophon Therapeutics' earnings last quarter? Bellerophon Therapeutics Inc (NASDAQ:BLPH) released its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. View Bellerophon Therapeutics' Earnings History. When is Bellerophon Therapeutics' next earnings date? Bellerophon Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Bellerophon Therapeutics. What price target have analysts set for BLPH? 2 analysts have issued 1 year target prices for Bellerophon Therapeutics' stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate Bellerophon Therapeutics' stock price to reach $2.50 in the next year. This suggests a possible upside of 568.4% from the stock's current price. View Analyst Price Targets for Bellerophon Therapeutics. What is the consensus analysts' recommendation for Bellerophon Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellerophon Therapeutics. What are Wall Street analysts saying about Bellerophon Therapeutics stock? Here are some recent quotes from research analysts about Bellerophon Therapeutics stock: 1. Maxim Group analysts commented, "Bellerophon reported 2Q19 with a net loss of ($4.1M) and $16.8M in cash on the balance sheet. At the current burn rate of ~$4M-$5M per quarter, the company should be funded through 1H20 and importantly through the next infection point; Cohort-2 data in PH-ILD expected by YE19." (8/9/2019) 2. According to Zacks Investment Research, "Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. " (5/15/2019) 3. HC Wainwright analysts commented, "Valuation and Risks. Our price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing." (1/29/2019) Has Bellerophon Therapeutics been receiving favorable news coverage? Press coverage about BLPH stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bellerophon Therapeutics earned a news impact score of -1.4 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Bellerophon Therapeutics. Are investors shorting Bellerophon Therapeutics? Bellerophon Therapeutics saw a drop in short interest in January. As of January 15th, there was short interest totalling 390,200 shares, a drop of 11.0% from the December 31st total of 438,300 shares. Based on an average daily trading volume, of 525,900 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.8% of the company's shares are short sold. View Bellerophon Therapeutics' Current Options Chain. Who are some of Bellerophon Therapeutics' key competitors? Some companies that are related to Bellerophon Therapeutics include Cyclerion Therapeutics (CYCN), Aquestive Therapeutics (AQST), Stealth BioTherapeutics (MITO), AVEO Pharmaceuticals (AVEO), Enlivex Therapeutics (ENLV), Bellicum Pharmaceuticals (BLCM), TFF Pharmaceuticals (TFFP), Oramed Pharmaceuticals (ORMP), Axovant Gene Therapies (AXGT), Sesen Bio (SESN), Proteostasis Therapeutics (PTI), Neos Therapeutics (NEOS), Trevi Therapeutics (TRVI), Inflarx (IFRX) and Trevena (TRVN). What other stocks do shareholders of Bellerophon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Aurinia Pharmaceuticals (AUPH), Onconova Therapeutics (ONTX), AVEO Pharmaceuticals (AVEO), Actinium Pharmaceuticals (ATNM), Biopharmx (BPMX), BIOLINERX LTD/S (BLRX), Inovio Pharmaceuticals (INO), Rexahn Pharmaceuticals (REXN) and Sorrento Therapeutics (SRNE). Who are Bellerophon Therapeutics' key executives? Bellerophon Therapeutics' management team includes the folowing people: Fabian Tenenbaum, Chief Executive Officer & DirectorAssaf Korner, Chief Financial Officer & SecretaryAmy Edmonds, VP-Clinical Operations & AdministrationMartin Dekker, Vice President-Engineering & ManufacturingPeter Fernandes, Chief Regulatory & Safety Officer When did Bellerophon Therapeutics IPO? (BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers. How do I buy shares of Bellerophon Therapeutics? Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Bellerophon Therapeutics' stock price today? One share of BLPH stock can currently be purchased for approximately $0.37. How big of a company is Bellerophon Therapeutics? Bellerophon Therapeutics has a market capitalization of $25.69 million. The biotechnology company earns $2.81 million in net income (profit) each year or ($0.34) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe.View Additional Information About Bellerophon Therapeutics. What is Bellerophon Therapeutics' official website? The official website for Bellerophon Therapeutics is http://www.bellerophon.com/. How can I contact Bellerophon Therapeutics? Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected] MarketBeat Community Rating for Bellerophon Therapeutics (NASDAQ BLPH)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 280 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 474MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe BLPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: What is Cost of Debt?
